ReviewProbiotics and antimicrobial proteins2026
Postbiotics: Novel Modulators of Gut Health, Metabolism, and Their Mechanisms of Action.
Review in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- The Nexus of Gut Microbiome, Microbial Metabolites, and Colonization Resistance Against Enteric Pathogens.Biomolecules · 2026Review
- Lactic Acid Bacteria-Derived Postbiotics in Dairy Foods: Definitions, Functions and Regulatory Challenges.Microorganisms · 2026Review
- Postbiotics in Functional Foods: Preparation-Based Characterization, Gut-Brain Axis Interactions, and Translational Perspectives.Foods (Basel, Switzerland) · 2026Review
- Postbiotics: An Overview and Recommendations for Improved Reporting.Molecular nutrition & food research · 2026Review
- Current Understanding of Probiotic Strains and Immune Function: From Gut Microbiota to Systemic Immunity.International journal of molecular sciences · 2026Review
- Review
- Anti-Inflammatory Effects ofFoods (Basel, Switzerland) · 2026Article
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postbiotics, defined as non-viable microbial cells, structural components, or metabolites, have recently emerged as promising modulators of gut health and metabolism. Unlike probiotics, they circumvent safety concerns associated with live microorganisms, including potential translocation, antibiotic resistance transfer, and viability loss during storage. Postbiotics encompass diverse bioactive compounds such as short-chain fatty acids (SCFAs), exopolysaccharides, bacteriocins, antioxidant enzymes, surface layer proteins, and bacterial lysates, each exerting distinct biological effects. Mechanistically, they enhance epithelial barrier function, regulate innate and adaptive immune responses, and modulate host gene expression through pattern recognition receptors and epigenetic modifications. SCFAs, particularly butyrate and propionate, improve intestinal homeostasis, insulin sensitivity, and anti-inflammatory signaling, while bacteriocins and EPSs display antibacterial, antiviral, anticancer, and immunomodulatory properties. Postbiotics also interfere with viral replication, inhibit pathogen adhesion, and attenuate inflammatory pathways, highlighting their multifunctional roles. Compared to probiotics and prebiotics, they offer superior safety, chemical stability, and clinical applicability, especially in vulnerable populations such as infants, elderly individuals, and immunocompromised patients. Preclinical and in vitro studies provide compelling evidence for their therapeutic potential in metabolic disorders, infections, cancer, and immune-mediated diseases; however, clinical data remain limited. Further research is required to establish standardized definitions, optimal formulations, dosing strategies, and regulatory frameworks to support their integration into functional nutrition and precision medicine. Collectively, postbiotics represent a next-generation approach to microbiota-targeted interventions, offering novel opportunities for disease prevention, adjunctive therapy, and the advancement of microbiome-based therapeutics.
Indexed as
Identifiers
41212512What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.